DYNDyne Therapeutics, Inc.

Healthcare
$15.61-4.9% 1Y

The financials

Dyne Therapeutics, Inc. by the numbers

The next results filing is expected around Nov 4, 2026, the same week as a year ago.

Dyne Therapeutics, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$182M−$116Mn/a
Net income−$179M−$111Mn/a
Diluted EPS−$1.08−$0.97n/a
On our screens:Most shorted stocks

Biotechnology

Ranks #78 of 194 by RyuScore

Compare peers
DNLI-1.5%
Denali Therapeutics Inc.
IRON-0.68%
Disc Medicine, Inc.
VKTX-5.6%
Viking Therapeutics, Inc.
TARS-5.6%
Tarsus Pharmaceuticals, Inc.
PBLS-8.9%
Parabilis Medicines, Inc.
ELVN-1.2%
Enliven Therapeutics, Inc.